- Diagnostic Différentiel
Drug Information for DARAPRIM (pyrimethamine) 25-mg Scored Tablets (GlaxoSmithKline): WARNINGS
- CLINICAL PHARMACOLOGY
- ADVERSE REACTIONS
- HOW SUPPLIED
- Diseases/Conditions Related to DARAPRIM (pyrimethamine) 25-mg Scored Tablets (GlaxoSmithKline)
- Liens externes liés à DARAPRIM (pyrimethamine) 25-mg Scored Tablets (GlaxoSmithKline)
The dosage of pyrimethamine required for the treatment of toxoplasmosis is 10 to 20 times the recommended antimalaria dosage and approaches the toxic level. If signs of folate deficiency develop (see ADVERSE REACTIONS), reduce the dosage or discontinue the drug according to the response of the patient. Folinic acid (leucovorin) should be administered in a dosage of 5 to 15 mg daily (orally, IV, or IM) until normal hematopoiesis is restored.
Data in 2 humans indicate that pyrimethamine may be carcinogenic: a 51-year-old female who developed chronic granulocytic leukemia after taking pyrimethamine for 2 years for toxoplasmosis,3 and a 56-year-old patient who developed reticulum cell sarcoma after 14 months of pyrimethamine for toxoplasmosis.4
Pyrimethamine has been reported to produce a significant increase in the number of lung tumors in mice when given intraperitoneally at doses of 25 mg/kg.5
DARAPRIM should be kept out of the reach of infants and children as they are extremely susceptible to adverse effects from an overdose. Deaths in pediatric patients have been reported after accidental ingestion.
- Drug Information Provided by National Library of Medicine (NLM).